5.60
-0.06 (-1.06%)
-0.06 (-1.06%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Clovis Oncology Inc | CLVS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.06 | -1.06% | 5.60 | 00:00:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.67 | 5.04 | 5.78 | 5.58 | 5.66 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.68 | 5.59 | 0.91 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 35,042 | 8,720,128 | $ 5.35 | $ 46,635,858 | 6,253,126 | 3.62 - 11.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:57 | 50 | $ 5.59 | USD |
Clovis Oncology Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 579.22M | 103.43M | 100.92M | $ 143.01M | $ - | -7.43 | -1.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Clovis Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLVS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.00 | 6.41 | 5.04 | 5.77 | 8,187,745 | -0.40 | -6.67% |
| 1 Month | 8.0772 | 11.10 | 5.04 | 7.50 | 10,003,940 | -2.48 | -30.67% |
| 3 Months | 4.84 | 11.10 | 4.41 | 6.90 | 8,204,017 | 0.76 | 15.7% |
| 6 Months | 5.10 | 11.10 | 4.08 | 6.35 | 6,284,659 | 0.50 | 9.8% |
| 1 Year | 7.88 | 11.10 | 3.62 | 6.60 | 6,113,467 | -2.28 | -28.93% |
| 3 Years | 60.13 | 65.24 | 2.93 | 10.95 | 4,379,674 | -54.53 | -90.69% |
| 5 Years | 21.52 | 99.45 | 2.93 | 19.00 | 3,362,746 | -15.92 | -73.98% |
Clovis Oncology Description
| Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo. |
